Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657797 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 656
- Enrollment target
NCT03657797: Completed Phase 2 study, sponsored by Nicox Ophthalmics.
NCT03657797 is a Phase 2 study that has completed, run by Nicox Ophthalmics. The registered enrollment target is 656 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (393% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03657797, a Phase 2 study, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 656 participants
- Enrollment target
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.
Primary Outcome
Participants used medication in both eyes for 4 weeks with one eye was designated the study eye at baseline. The study eye was defined as the eye with the highest mean diurnal intraocular pressure (IOP) value at baseline (or the right eye if both eyes had the same IOP value at baseline). Mean diurnal IOP at week 4 is the average of the 8AM, 10AM and 4PM IOPs at week 4.
Interventions
- DRUG Latanoprost 0.005%
- DRUG NCX 470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 656 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 2 |
What the finished NCT03657797 record still lists
NCT03657797 is an interventional study that assigns participants to a tested intervention. The registered 656 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (393% higher).
The record links to 0 conditions, and to 2 interventions - of which Latanoprost 0.005% is the first listed.
NCT03657797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03657797 about?
NCT03657797 is a clinical study titled "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) wi...
What is the current status of trial NCT03657797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 656 participants. The study started on 2018-08-01. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT03657797?
The interventions under investigation include: Latanoprost 0.005% (DRUG), NCX 470 (DRUG).
Who is sponsoring clinical trial NCT03657797?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03657797's enrollment target sits among peer trials
656 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI